Denise Zembryki
Providence College(US)GlaxoSmithKline (Netherlands)(NL)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Brain Metastases and Treatment, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer(2009)661 cited
- → Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases(2011)160 cited
- → Design of potent and selective human cathepsin K inhibitors that span the active site(1997)119 cited
- → An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer(2009)86 cited
- → EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)(2007)71 cited
- → Structure Activity Relationships of 5-, 6-, and 7-Methyl-Substituted Azepan-3-one Cathepsin K Inhibitors(2006)70 cited
- → Development and Characterization of a Human In Vitro Resorption Assay: Demonstration of Utility Using Novel Antiresorptive Agents(1999)46 cited
- → Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU)(2008)44 cited
- → (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase(1998)36 cited
- → Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model(1999)35 cited